Axim Biotechnologies annual ebitda margin
2015
2016
2017
2018
2019
2021
2022
2023
2024
Axim Biotechnologies EBITDA Margin Growth & History (AXIM)
Axim Biotechnologies's ebitda margin was −3,479.97% for fiscal 2024.
View full Axim Biotechnologies company overviewAxim Biotechnologies annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −3,479.97% | +2400.44 pp |
| 2023 | 2023-12-31 | −5,880.41% | +41743.77 pp |
| 2022 | 2022-12-31 | −47,624.18% | −28009.04 pp |
| 2021 | 2021-12-31 | −19,615.14% | — |
| 2019 | 2019-12-31 | −388.04% | +2179.93 pp |
| 2018 | 2018-12-31 | −2,567.97% | +4044.46 pp |
| 2017 | 2017-12-31 | −6,612.43% | +1369.27 pp |
| 2016 | 2016-12-31 | −7,981.70% | +12467.29 pp |
| 2015 | 2015-12-31 | −20,448.99% | — |
Axim Biotechnologies quarterly ebitda margin
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2024 | 2024-06-30 | −2,639.24% | +3312.76 pp |
| Q1 2024 | 2024-03-31 | −554.10% | +7609.74 pp |
| Q4 2023 | 2023-12-31 | −5,131.92% | +8558.90 pp |
| Q3 2023 | 2023-09-30 | −5,028.49% | +87146.24 pp |
| Q2 2023 | 2023-06-30 | −5,952.00% | — |
| Q1 2023 | 2023-03-31 | −8,163.84% | — |
| Q4 2022 | 2022-12-31 | −13,690.82% | +101758.05 pp |
| Q3 2022 | 2022-09-30 | −92,174.73% | −51919.77 pp |
| Q4 2021 | 2021-12-31 | −115,448.87% | — |
| Q3 2021 | 2021-09-30 | −40,254.96% | — |
| Q2 2021 | 2021-06-30 | −14,616.50% | — |
| Q1 2021 | 2021-03-31 | −2,639.13% | — |
| Q4 2019 | 2019-12-31 | 32.82% | +465.40 pp |
| Q1 2019 | 2019-03-31 | −13,439.01% | +779.70 pp |
| Q4 2018 | 2018-12-31 | −432.59% | +6358.03 pp |
| Q3 2018 | 2018-09-30 | −15,022.28% | −2886.52 pp |
| Q2 2018 | 2018-06-30 | −16,395.44% | −4720.48 pp |
| Q1 2018 | 2018-03-31 | −14,218.71% | −11665.08 pp |
| Q4 2017 | 2017-12-31 | −6,790.62% | −490.90 pp |
| Q3 2017 | 2017-09-30 | −12,135.77% | +4059.38 pp |
| Q2 2017 | 2017-06-30 | −11,674.96% | −7310.17 pp |
| Q1 2017 | 2017-03-31 | −2,553.64% | +4167.83 pp |
| Q4 2016 | 2016-12-31 | −6,299.72% | +34620.48 pp |
| Q3 2016 | 2016-09-30 | −16,195.15% | −8372.64 pp |
| Q2 2016 | 2016-06-30 | −4,364.79% | +8519.12 pp |
| Q1 2016 | 2016-03-31 | −6,721.46% | — |
| Q4 2015 | 2015-12-31 | −40,920.20% | — |
| Q3 2015 | 2015-09-30 | −7,822.50% | — |
| Q2 2015 | 2015-06-30 | −12,883.91% | — |
Axim Biotechnologies ebitda margin trends
Over the last five fiscal years, Axim Biotechnologies's ebitda margin decreased from −388.04% to −3,479.97%, a change of −3091.93 percentage points. The latest reported quarter, Q2 2024, shows −2,639.24%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axim Biotechnologies source filings ↗